Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 29

Sort by

Sort Order Select

Journal Articles

Updated Meta-Analysis of Randomized Controlled Trials on Primary Ambulatory Thromboprophylaxis (PATP) in Patients with Advanced Pancreatic Cancer (APC) Receiving Chemotherapy

Kyaw Zin Thein, MDMBBS, Donald P. Quick, MD, Thein H. Oo, MD

Blood (2019) 134 (Supplement_1): 3469.

https://doi.org/10.1182/blood-2019-128674

Published: 2019

Journal Articles

A Systematic Review and Meta- Analysis of Randomized Controlled Trials on Primary Ambulatory Thromboprophylaxis (PATP) in Patients with Gastrointestinal Cancers Receiving Chemotherapy

Kyaw Zin Thein, MDMBBS, Donald P. Quick, MD, Thein Hlaing Oo, MD

Blood (2019) 134 (Supplement_1): 3679.

https://doi.org/10.1182/blood-2019-126732

Published: 2019

Journal Articles

Interferon in Polycythemia Vera (PV) Yields Improved Myelofibrosis-Free and Overall Survival

Ghaith Abu Zeinah, MD, Spencer Krichevsky, BS, Diana Jaber, BA, Niamh Savage, BA, Claudia Sosner, BA, Gabriela Hoberman, BA, Ellen K. Ritchie, MD, Andrew I. Schafer, MD, Joseph Scandura, MD PhD, Richard T. Silver, MD

Blood (2019) 134 (Supplement_1): 2942.

https://doi.org/10.1182/blood-2019-130265

Published: 2019

Journal Articles

Updated Meta-Analysis of Randomized Controlled Trials on Primary Ambulatory Thromboprophylaxis (PATP) in Patients with Locally Advanced or Metastatic Lung Cancer Receiving Chemotherapy

Kyaw Zin Thein, MDMBBS, Lukman Tijani, MD, Thein H. Oo, MD

Blood (2019) 134 (Supplement_1): 2435.

https://doi.org/10.1182/blood-2019-123144

Published: 2019

Journal Articles

Medically Ill Patients with Moderate Renal Insufficiency Have More Thrombotic and Bleeding Events Than Those with Normal Renal Function: Insights from the Magellan and Mariner Trials of Extended Thrombprophylaxis

Jeffrey I. Weitz, MD, Gary E. Raskob, PhD, Alex C. Spyropoulos, MD, Alexander T Cohen, MD, Theodore E. Spiro, MD, Yoriko De Sanctis, MS, Jianfeng Xu, PhD, Eunyoung Suh, PhD, Wentao Lu, PhD, Concetta Lipardi, MDPhD, Elliot S. Barnathan, MD

Blood (2018) 132 (Supplement 1): 1236.

https://doi.org/10.1182/blood-2018-99-111911

Published: 2018

Journal Articles

Low Body Mass Index in Pregnant Women with Sickle Cell Disease Is Associated with Premature Delivery in Sub- Saharan Africa

Eugenia Vicky Asare, MBChB, BSc, Edeghonghon Olayemi, MBBS, MSc, Yvonne Adomakoh, MBBS, Enoch Mensah, HND, Alim Swarray-Deen, MD, Harriet Ghansah, BSc, Yvonne Osei-Bonsu, Dip(PH), Selina Crabbe, Dip(PH), Latif Musah, BSc, Charles Hayfron-Benjamin, MBChB, Theodore Boafor, MBChB, Brittany Covert, MPH, CCRP, Adetola A. Kassim, MD MS, Andra H. James, MDMPH, Mark Rodeghier, PhD, Michael R. DeBaun, MD MPH, Samuel A Oppong, MD

Blood (2017) 130 (Supplement 1): 2250.

https://doi.org/10.1182/blood.V130.Suppl_1.2250.2250

Published: 2017

Journal Articles

Early Disease Progression Predicts Poorer Survival in Patients with Follicular Lymphoma (FL) in the GALLIUM Study

Aino Launonen, Wolfgang Hiddemann, MD PhD, Ulrich Duenzinger, Günter Fingerle-Rowson, Tina Nielsen, Robert Marcus

Blood (2017) 130 (Supplement 1): 1490.

https://doi.org/10.1182/blood.V130.Suppl_1.1490.1490

Published: 2017

Journal Articles

A Systematic Review and Meta-Analysis of Randomized Controlled Trials (RCT) in Ambulatory Thromboprophylaxis (ATP) in Patients with Lung Cancer Receiving Chemotherapy

Kyaw Zin Thein, MD MBBS, Sai-Ching J Yeung, MD PhD FACP, Thein H. Oo, MD FACP, FRCP

Blood (2016) 128 (22): 3825.

https://doi.org/10.1182/blood.V128.22.3825.3825

Published: 2016

Journal Articles

Lenalidomide Maintenance after Front Line Therapy Substantially Prolongs Progression Free Survival in High Risk CLL: Interim Results of a Phase 3 Study (CLL M1 study of the German CLL Study Group)

Blood (2016) 128 (22): 229.

https://doi.org/10.1182/blood.V128.22.229.229

Published: 2016

Journal Articles

Dalteparin Thromboprophylaxis in Cancer Patients at High Risk for Venous Thromboembolism: A Randomized Trial

Alok A. Khorana, MD, Charles W. Francis, Nicole Kuderer, MD, Marc Carrier, MD, Thomas L. Ortel, MD, PhD, Ted Wun, MD, Derick Peterson, Renuka Iyer, Gary H. Lyman, MD MPH

Blood (2015) 126 (23): 427.

https://doi.org/10.1182/blood.V126.23.427.427

Published: 2015

Journal Articles

Benefit of Extended Maintenance Therapy for Venous Thromboembolism with Dabigatran Etexilate Is Maintained Over 1 Year of Post-Treatment Follow-up

Sam Schulman, MD, PhD, David Baanstra, MD, Henry Eriksson, MD, Samuel Z. Goldhaber, MD, Ajay Kakkar, MD, Clive Kearon, MD, PhD, Sebastian Schellong, MD, Jeffrey Friedman, MD

Blood (2012) 120 (21): 21.

https://doi.org/10.1182/blood.V120.21.21.21

Published: 2012

Journal Articles

Activated Protein C, Sepsis, and the Innate Immune Response to Infection

Hartmut Weiler, PhD, John H. Griffin, PhD

Blood (2012) 120 (21): SCI-43.

https://doi.org/10.1182/blood.V120.21.SCI-43.SCI-43

Published: 2012

Journal Articles

Anticoagulation in Ambulatory Cancer Patients

Allyson Pishko, BS, Kenneth J. Smith, MD, MS, Margaret V. Ragni, MD, MPH

Blood (2011) 118 (21): 2071.

https://doi.org/10.1182/blood.V118.21.2071.2071

Published: 2011

Journal Articles

Low Molecular Weight Heparin Thromboprophylaxis in Ambulatory Cancer Patients: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.

Nicole M. Kuderer, MD, Thomas L. Ortel, MD, PhD, Alok A Khorana, MD, Charles W. Francis, MD, Gary H. Lyman, MD, MPH

Blood (2009) 114 (22): 490.

https://doi.org/10.1182/blood.V114.22.490.490

Published: 2009

Journal Articles

Once-Daily Oral Rivaroxaban Versus Placebo in the Long-Term Prevention of Recurrent Symptomatic Venous Thromboembolism. the Einstein-Extension Study

Harry Roger Buller, MD, PhD

Blood (2009) 114 (22): LBA-2.

https://doi.org/10.1182/blood.V114.22.LBA-2.LBA-2

Published: 2009

Journal Articles

Indirect Comparisons of Rivaroxaban Versus Alternative Prophylaxes for the Prevention of VTE in Patients Undergoing Total Knee Replacement.

Alexander Diamantopoulos, Corrine LeReun, Farhat Rasul, Michael Lees, Maria Kubin, Philip Wells, MD, FRCPC, MSc

Blood (2008) 112 (11): 1292.

https://doi.org/10.1182/blood.V112.11.1292.1292

Published: 2008

Journal Articles

Once-Daily Oral Rivaroxaban Compared with Subcutaneous Enoxaparin Every 12 Hours for Thromboprophylaxis after Total Knee Replacement: RECORD4

Alexander GG Turpie, MD, Kenneth A. Bauer, MD, Bruce Davidson, MD, Michael Gent, MD, Louis Kwong, MD, Michael Rud Lassen, MD, Fred Cushner, MD, Paul Lotke, MD, Scott D. Berkowitz, MD, FACP, Tiemo Joerg Bandel, Frank Misselwitz, MD, William Fisher, MD

Blood (2008) 112 (11): 35.

https://doi.org/10.1182/blood.V112.11.35.35

Published: 2008

Journal Articles

The Impact of Age on the Efficacy and Safety of Extended-Duration Thromboprophylaxis in Acutely Ill Medical Patients with Recent Immobility: A Sub-Group Analysis from the EXCLAIM Study

Roger D Yusen, Russell D Hull, Sebastian M Schellong, Victor F Tapson, Manuel Monreal, Michel Meyer Samama, Min Chen, Alexander GG Turpie

Blood (2008) 112 (11): 438.

https://doi.org/10.1182/blood.V112.11.438.438

Published: 2008

Journal Articles

A Randomized Double-Blind Placebo-Controlled Study on Nadroparin for Prophylaxis of Thromboembolic Events in Cancer Patients Receiving Chemotherapy: The PROTECHT Study

Giancarlo Agnelli, M.D., Gualberto Gussoni, M.D., Carlo Bianchini, M.D., Melina Verso, M.D., Maurizio Tonato, M.D.

Blood (2008) 112 (11): 6.

https://doi.org/10.1182/blood.V112.11.6.6

Published: 2008

Journal Articles

Extended Thromboprophylaxis with Rivaroxaban Compared with Short-Term Thromboprophylaxis with Enoxaparin after Total Hip Arthroplasty: The RECORD2 Trial.

Ajay K. Kakkar, MD, PhD, Benjamin Brenner, MD, Ola E. Dahl, MD, PhD, Bengt I. Eriksson, MD, PhD, Patrick Mouret, MD, Jim Muntz, MD, Tiemo J. Bandel, MD, Frank Misselwitz, MD, PhD, Sylvia Haas, MD

Blood (2007) 110 (11): 307.

https://doi.org/10.1182/blood.V110.11.307.307

Published: 2007

NARROW

Updated Meta-Analysis of Randomized Controlled Trials on Primary Ambulatory Thromboprophylaxis (PATP) in Patients with Advanced Pancreatic Cancer (APC) Receiving Chemotherapy

A Systematic Review and Meta- Analysis of Randomized Controlled Trials on Primary Ambulatory Thromboprophylaxis (PATP) in Patients with Gastrointestinal Cancers Receiving Chemotherapy

Interferon in Polycythemia Vera (PV) Yields Improved Myelofibrosis-Free and Overall Survival

Updated Meta-Analysis of Randomized Controlled Trials on Primary Ambulatory Thromboprophylaxis (PATP) in Patients with Locally Advanced or Metastatic Lung Cancer Receiving Chemotherapy

Medically Ill Patients with Moderate Renal Insufficiency Have More Thrombotic and Bleeding Events Than Those with Normal Renal Function: Insights from the Magellan and Mariner Trials of Extended Thrombprophylaxis

Low Body Mass Index in Pregnant Women with Sickle Cell Disease Is Associated with Premature Delivery in Sub- Saharan Africa

Early Disease Progression Predicts Poorer Survival in Patients with Follicular Lymphoma (FL) in the GALLIUM Study

A Systematic Review and Meta-Analysis of Randomized Controlled Trials (RCT) in Ambulatory Thromboprophylaxis (ATP) in Patients with Lung Cancer Receiving Chemotherapy

Lenalidomide Maintenance after Front Line Therapy Substantially Prolongs Progression Free Survival in High Risk CLL: Interim Results of a Phase 3 Study (CLL M1 study of the German CLL Study Group)

Dalteparin Thromboprophylaxis in Cancer Patients at High Risk for Venous Thromboembolism: A Randomized Trial

Benefit of Extended Maintenance Therapy for Venous Thromboembolism with Dabigatran Etexilate Is Maintained Over 1 Year of Post-Treatment Follow-up

Activated Protein C, Sepsis, and the Innate Immune Response to Infection

Anticoagulation in Ambulatory Cancer Patients

Low Molecular Weight Heparin Thromboprophylaxis in Ambulatory Cancer Patients: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.

Once-Daily Oral Rivaroxaban Versus Placebo in the Long-Term Prevention of Recurrent Symptomatic Venous Thromboembolism. the Einstein-Extension Study

Indirect Comparisons of Rivaroxaban Versus Alternative Prophylaxes for the Prevention of VTE in Patients Undergoing Total Knee Replacement.

Once-Daily Oral Rivaroxaban Compared with Subcutaneous Enoxaparin Every 12 Hours for Thromboprophylaxis after Total Knee Replacement: RECORD4

The Impact of Age on the Efficacy and Safety of Extended-Duration Thromboprophylaxis in Acutely Ill Medical Patients with Recent Immobility: A Sub-Group Analysis from the EXCLAIM Study

A Randomized Double-Blind Placebo-Controlled Study on Nadroparin for Prophylaxis of Thromboembolic Events in Cancer Patients Receiving Chemotherapy: The PROTECHT Study

Extended Thromboprophylaxis with Rivaroxaban Compared with Short-Term Thromboprophylaxis with Enoxaparin after Total Hip Arthroplasty: The RECORD2 Trial.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only